Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
URC102 Safety and PK/PD in Renal Impairment and Healthy Volunteers
NCT05198778Phase 1Completed
- Sponsor
- JW Pharmaceutical Corporation
- Start
- Nov 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of epaminurad in gout and hyperuricemia (3 arms), sponsored by JW Pharmaceutical Corporation. Primary endpoints: Area under the plasma concentration-time curve at 72 hours and Maximum concentration of drug in plasma at 72 hours. Started Nov 2021; status: completed.
02
Drugs
epaminurad
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on NCT05198778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05198778.